Shorts On Watch: What’s Next for BIO-MATRIX SCIENTIFI (OTCMKTS:BMSN) After Having More Shares Shorted?

November 28, 2016 - By Clifton Ray   ·   0 Comments

Shorts On Watch: What's Next for BIO MATRIX SCIENTIFI (OTCMKTS:BMSN) After Having More Shares Shorted?

The stock of BIO-MATRIX SCIENTIFI (OTCMKTS:BMSN) registered an increase of 1800% in short interest. BMSN’s total short interest was 9,500 shares in November as published by FINRA. Its up 1800% from 500 shares, reported previously. The stock closed at $0.0001 during the last session. It is down 50.00% since April 29, 2016 and is downtrending. It has underperformed by 56.01% the S&P500.

Bio-Matrix Scientific Group, Inc. is a development-stage company. The company has a market cap of $574,640. The Company, through its subsidiary, Regen BioPharma, Inc., is engaged in the development of regenerative medical applications, which it focuses to license from other entities up to the point of completion of Phase I and or Phase II clinical trials, after which it would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. It currently has negative earnings. The Firm focuses on developing HemaXellerate I, a cellular therapy designed to heal damaged bone marrow.

BMSN Company Profile

Bio-Matrix Scientific Group, Inc., incorporated on October 6, 1998, is a development-stage company. The Company, through its subsidiary, Regen Biopharma, Inc., is engaged in the development of regenerative medical applications, which it focuses to license from other entities up to the point of completion of Phase I and or Phase II clinical trials, after which it would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.

More notable recent Bio Matrix Scientific Group Inc (OTCMKTS:BMSN) news were published by: Marketwired.com which released: “Bio-Matrix Scientific Group’s Subsidiary, Regen BioPharma Announces dCellVax …” on September 25, 2013, also Marketwired.com with their article: “Cell Therapy Expert Dr. Amit Patel Joins Regen BioPharma Inc. Scientific …” published on October 15, 2014, Marketwired.com published: “Regen BioPharma Inc. Announces Preferred Stock Dividend” on February 25, 2015. More interesting news about Bio Matrix Scientific Group Inc (OTCMKTS:BMSN) were released by: Marketwired.com and their article: “Regen BioPharma, Inc. Comments on dCellVax Cancer IDO-Targeting Technology in …” published on February 24, 2015 as well as Marketwired.com‘s news article titled: “FDA Issues IND Number for Regen BioPharma’s dCellVax Therapeutic Application …” with publication date: November 04, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Clifton Ray


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>